W
William G. Ondo
Researcher at Houston Methodist Hospital
Publications - 38
Citations - 1276
William G. Ondo is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Essential tremor & Restless legs syndrome. The author has an hindex of 15, co-authored 38 publications receiving 977 citations. Previous affiliations of William G. Ondo include Case Western Reserve University & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.
Barbara Schormair,Chen Zhao,Steven Bell,Erik Tilch,Aaro V. Salminen,Benno Pütz,Yves Dauvilliers,Ambra Stefani,Birgit Högl,Werner Poewe,David Kemlink,Karel Sonka,Cornelius G. Bachmann,Walter Paulus,Claudia Trenkwalder,Wolfgang H. Oertel,Magdolna Hornyak,Maris Teder-Laving,Andres Metspalu,Georgios M. Hadjigeorgiou,Olli Polo,Ingo Fietze,Owen A. Ross,Zbigniew K. Wszolek,Adam S. Butterworth,Nicole Soranzo,Willem H. Ouwehand,David J. Roberts,John Danesh,Richard P. Allen,Christopher J. Earley,William G. Ondo,Lan Xiong,Jacques Montplaisir,Ziv Gan-Or,Markus Perola,Pavel Vodicka,Christian Dina,Andre Franke,Lukas Tittmann,Alexandre F.R. Stewart,Svati H. Shah,Christian Gieger,Annette Peters,Guy A. Rouleau,Klaus Berger,Konrad Oexle,Emanuele Di Angelantonio,David A. Hinds,Bertram Müller-Myhsok,Juliane Winkelmann +50 more
TL;DR: A meta-analysis of genome-wide association studies (GWASs) to identify potential molecular targets and identified and replicated 13 new risk loci for restless legs syndrome and confirmed the previously identified sixrisk loci.
Journal ArticleDOI
Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
John W. Winkelman,Melissa J. Armstrong,Richard P. Allen,K. Ray Chaudhuri,William G. Ondo,Claudia Trenkwalder,Phyllis C. Zee,Gary S. Gronseth,David Gloss,Theresa A. Zesiewicz +9 more
TL;DR: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms and may consider prescribing ropinirole, levodopa, or exercise.
Journal ArticleDOI
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Robert A. Hauser,Mark F. Lew,Howard I. Hurtig,William G. Ondo,Joanne Wojcieszek,Cheryl Fitzer-Attas,Frederick J. Marshall,Irenita Gardiner,Nancy Pearson,Debra Berry,Kathleen M. Shannon,Jean A. Jaglin,William G. Ondo,Christine Hunter,Cathy R. Anderson,Peter A. LeWitt,Patricia Kaminski,Dawn Miller,Maryan DeAngelis,Janis M. Miyasaki,Julie So,Lisa Johnston,Caroline M. Tanner,Tracy Stewart,Lisa Tagg,Sheila Everett,Georgia Germain,Mickie Welsh,Micki McCollister,Linda L. Mann,Carlos Singer,William C. Koller,William J. Weiner,Dinorah Bateman,Tilak Mendis,Melodie Moterson,Cynthia Alcorn-Costa,Keely Haas,Peggy Gray,Davoud Mohtat,Neila Mendis,Laura Sutherland,Howard H. Hurtig,Mary Lloyd,Mary Mathews,Robert Hauser,Lisa Gauger,Patricia Dyches,Cheryl Newcomb,Jean P. Hubble,Karen Betcher,Carolyn C. Weeks,Sandra K. Kostyk,Ali H. Rajput,Marlene Gerow,Linda Klassen,Marianne Ewasnishin,Lawrence I. Golb,Vanessa Patterson,Deborah L. Caputo,Patricia Seuffert,Rajesh Pahwa,Tamara Gales,Lorette J. Jenkins,Amy Parsons,Scott Cradr,Jovianna N. Wellinghoff,Shantelle Coe,Cheryl Armstrong,Connie Kawai,Katherine B. Hawthorne,Kellie Gelles,Xiaoming Lu,Suzanne W. Schuman,Cheryl Cooper,Kenneth Marek,Barbara Fussell,Karen Caplan,Erica Barnabei,Karen Stavris,Kapil D. Sethi,J. Carpenter,James B. Osborne,Shoba Narayan,K. Ligon,Eric Molho,Sharon Evans,Jacqueline Nash,Diane Brown,Mark Stacy,Kelli Williamson,Peter Novak,Robert G. Feldman,Cathi A. Thomas,W.R. Wayne Martin,Pam King,Germanine McInnes,Shaunna Caouette,Jo Belden,Andew Feigin,Jean Ayan,Barbara Shannon,Charles H. Adler,Stephanie Newman,Teri Radam,Myrna Schear,Naomi Santoni,Sharon Wortzel,Nancy Saton,Paul J. Tuite,Susan Rolandelli,Jody Lowery,Brenda Ebbitt,Adrienne Baranauskas,Michael J. Aminoff,Mirann DiMinno,Jessie Roth,Tracey Borst,Julie Hevezi,Carolyn Deloa,Tracey Tam,Anita Lopez,John M. Bertoni,Larisa I. Skrypnik,Carolyn Peterson,Mark Forrest Gordon,Roberta Winnick,Sharyn Parness,Joanne Hamann,Vincent Calabrese,Peggy Roberge,Paul Atchison,Cathy W. Allen,Susan Rolli,Arif Dalvi,Un Jung Kang,Judy Richman,Shirley Uy +137 more
TL;DR: Compared to delayed start, early initiation of rasagiline provided long‐term clinical benefit, even in the face of treatment with other dopaminergic agents.
Journal ArticleDOI
Randomized controlled trial of deutetrabenazine for tardive dyskinesia the ARM-TD study
Hubert H. Fernandez,Stewart A. Factor,Robert A. Hauser,Joohi Jimenez-Shahed,William G. Ondo,L. Fredrik Jarskog,Herbert Y. Meltzer,Scott W. Woods,Danny Bega,Mark S. LeDoux,David Shprecher,Charles S. Davis,Mat D. Davis,David Stamler,Karen E. Anderson +14 more
TL;DR: In patients with tardive dyskinesia, deutetrabenazine was well tolerated and significantly reduced abnormal movements, providing Class I evidence that in patients with TD, AIMS scores are reduced.
Journal ArticleDOI
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Karen E. Anderson,David Stamler,Mat D. Davis,Stewart A. Factor,Robert A. Hauser,Jouko Isojärvi,L. Fredrik Jarskog,Joohi Jimenez-Shahed,Rajeev Kumar,Joseph P. McEvoy,Stanislaw Ochudlo,William G. Ondo,Hubert H. Fernandez +12 more
TL;DR: This double-blind, randomised, placebo-controlled, phase 3 trial aimed to assess the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients with tardive dyskinesia.